$BRST
Broad Street Realty, Inc.

2019 Q3 Form 10-Q Financial Statement

#000143774919016367 Filed on August 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2019 Q1
Revenue $0.00 $0.00 $1.580M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.030K $144.6K $119.3K
YoY Change -93.23% 60.66% -43.2%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $808.00 $808.00 $4.000K
YoY Change 0.0% 0.0% 395.05%
% of Gross Profit
Operating Expenses $9.030K $1.907M $2.011M
YoY Change -93.23% 2018.89% 857.62%
Operating Profit -$9.034K -$291.0K -$431.0K
YoY Change -93.23% 235.48% 106.42%
Interest Expense $328.00 $82.00K $69.00K
YoY Change 28.13% 21254.17% 17868.75%
% of Operating Profit
Other Income/Expense, Net -$141.0K -$294.0K
YoY Change
Pretax Income -$9.360K -$145.1K -$119.8K
YoY Change -93.0% 61.2% -42.97%
Income Tax
% Of Pretax Income
Net Earnings -$9.362K -$145.1K -$119.8K
YoY Change -93.0% 66.52% -42.75%
Net Earnings / Revenue -7.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.585K -$55.57K -$45.88K
COMMON SHARES
Basic Shares Outstanding 2.611M 2.611M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.23K $4.750K $76.47K
YoY Change -87.72% -98.68% -84.07%
Cash & Equivalents $348.0K $427.0K $173.0K
Short-Term Investments
Other Short-Term Assets $11.03K $11.01K $23.51K
YoY Change -75.96% -44.95% -21.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.26K $15.76K $99.99K
YoY Change -85.96% -95.81% -80.39%
LONG-TERM ASSETS
Property, Plant & Equipment $16.15K $16.96K $17.77K
YoY Change -16.67% -16.01% -15.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $16.15K $16.96K $17.77K
YoY Change -16.67% -69.05% -15.39%
TOTAL ASSETS
Total Short-Term Assets $43.26K $15.76K $99.99K
Total Long-Term Assets $16.15K $16.96K $17.77K
Total Assets $59.42K $32.72K $117.8K
YoY Change -81.87% -92.41% -77.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $267.3K $223.1K $150.5K
YoY Change 520.74% 346.1% 201.02%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $8.180K $20.68K
YoY Change -100.0% -18.2% 3.4%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $294.7K $258.6K $198.6K
YoY Change 153.82% 201.75% 101.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $294.7K $258.6K $198.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $294.7K $258.6K $198.6K
YoY Change 153.82% 201.75% 101.33%
SHAREHOLDERS EQUITY
Retained Earnings -$112.1M -$112.1M -$112.0M
YoY Change 0.4% 0.51% 0.46%
Common Stock $26.11K $26.11K $26.11K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$235.2K -$225.9K -$80.79K
YoY Change
Total Liabilities & Shareholders Equity $59.42K $32.72K $117.8K
YoY Change -81.87% -92.41% -77.82%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$9.362K -$145.1K -$119.8K
YoY Change -93.0% 66.52% -42.75%
Depreciation, Depletion And Amortization $808.00 $808.00 $4.000K
YoY Change 0.0% 0.0% 395.05%
Cash From Operating Activities $35.68K -$59.23K -$772.0K
YoY Change -143.08% -46.15% 256.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$344.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.180K -12.50K 1.151M
YoY Change 156.43% -37.5% -9308.0%
NET CHANGE
Cash From Operating Activities 35.68K -59.23K -772.0K
Cash From Investing Activities -344.0K
Cash From Financing Activities -8.180K -12.50K 1.151M
Net Change In Cash 27.50K -71.73K 35.00K
YoY Change -131.97% -44.82% -115.28%
FREE CASH FLOW
Cash From Operating Activities $35.68K -$59.23K -$772.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
mamp
mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
263860
mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
295542
CY2019Q2 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
144589
CY2018Q2 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
86741
CY2018Q3 mamp Monthly Costs For Overhead Items
MonthlyCostsForOverheadItems
5000
CY2018Q2 mamp Net Working Deficit
NetWorkingDeficit
-243000
mamp Percentage Of Income Tax Examination Likelihood Of Tax Benefits Being Realized Upon Settlement
PercentageOfIncomeTaxExaminationLikelihoodOfTaxBenefitsBeingRealizedUponSettlement
0.5
CY2019Q2 mamp Preferred Stock Amount Of Preferred Dividends Undeclared And Unaccrued
PreferredStockAmountOfPreferredDividendsUndeclaredAndUnaccrued
12500
CY2018Q4 mamp Preferred Stock Amount Of Preferred Dividends Undeclared And Unaccrued
PreferredStockAmountOfPreferredDividendsUndeclaredAndUnaccrued
10000
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
CY2018 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
0
dei Entity Registrant Name
EntityRegistrantName
MedAmerica Properties Inc.
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000764897
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2610568
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
CY2018 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
CY2019Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
223049
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
92566
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5656
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4040
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500
CY2019Q2 us-gaap Assets
Assets
32719
CY2018Q4 us-gaap Assets
Assets
192081
CY2019Q2 us-gaap Assets Current
AssetsCurrent
15759
CY2018Q4 us-gaap Assets Current
AssetsCurrent
173505
CY2019Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
16960
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
18576
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Basis of Presentation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.7pt;text-align:left;text-indent:37.4pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:34.1pt;">The accompanying Financial Statements give effect to all adjustments necessary to present fairly the financial position and results of operations and cash flows of the Company.&nbsp; In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2019 </div>the Company dissolved all of its pre-merger subsidiaries which were inactive. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2019 </div>the Company formed various subsidiaries which are inactive except for the execution of the Merger Agreements referenced above.</div></div>
CY2018Q2 us-gaap Cash
Cash
4745
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139721
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
708382
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4745
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
357903
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-134976
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-350479
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
26105
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
26105
CY2019Q2 us-gaap Depreciation
Depreciation
808
us-gaap Depreciation
Depreciation
1616
CY2018Q2 us-gaap Depreciation
Depreciation
808
us-gaap Depreciation
Depreciation
1616
CY2019Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5650
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
130483
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16171
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
34614
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-22770
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-20000
us-gaap Interest Expense
InterestExpense
985
us-gaap Interest Expense
InterestExpense
768
CY2019Q2 us-gaap Interest Expense
InterestExpense
492
CY2018Q2 us-gaap Interest Expense
InterestExpense
384
us-gaap Interest Paid Net
InterestPaidNet
985
us-gaap Interest Paid Net
InterestPaidNet
768
CY2019Q2 us-gaap Liabilities
Liabilities
258594
CY2018Q4 us-gaap Liabilities
Liabilities
153111
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32719
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
192081
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
258594
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
153111
CY2019Q2 us-gaap Loans Payable Current
LoansPayableCurrent
8184
CY2018Q4 us-gaap Loans Payable Current
LoansPayableCurrent
33184
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Nature of Operations</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.7pt;text-align:left;text-indent:37.4pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:34.1pt;">MedAmerica Properties Inc. (the &#x201c;Company&#x201d; or &#x201c;MedAmerica&#x201d;) was originally organized under the laws of the Commonwealth of Massachusetts in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1985,</div> under the name VMS Hotel Investment Trust, for the purpose of investing in mortgage loans. The Company was subsequently reorganized as a Delaware corporation in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1987</div> and changed its name to B.H.I.T. Inc. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> the Company changed its name from B.H.I.T. Inc. to Banyan Rail Services Inc. From <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the Company experienced severe losses from an operating subsidiary in the rail services sector. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> after exploring various industries and researching numerous companies, the board of directors elected to pursue investing in commercial real estate. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company began negotiating a transaction with a sponsor of real estate properties located in the United States. The Company entered into a letter of intent with the sponsor in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018, </div>which was amended in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 28, 2019, </div>the Company and certain of its newly formed subsidiaries described further below entered into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div> separate agreements and plans of merger (collectively, the &#x201c;Merger Agreements&#x201d; and the &#x201c;Transaction&#x201d;) with each of Broad Street Realty, LLC (the &#x201c;BSR&#x201d;), Broad Street Ventures, LLC (&#x201c;BSV&#x201d;) and each of BSV Avondale LLC, BSV Colonial Investors LLC, BSV Coral Hills Investors LLC, BSV Crestview Square LLC, BSV Cromwell Parent LLC, BSV Cypress Point Investors LLC, BSV Dekalb LLC, BSV Greenwood Investors LLC, BSV Highlandtown Investors LLC, BSV Hollinswood LLC, BSV Lamont Investors LLC, BSV Lamonticello Investors LLC, BSV LSP East Investors LLC, BSV Patrick Street Member LLC, BSV Premier Brookhill LLC, BSV Spotswood Investors LLC and BSV West Broad Investors LLC (collectively, the &#x201c;Broad Street Entities&#x201d;). Pursuant to the Merger Agreements, in a series of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div> mergers, BSR, BSV and each Broad Street Entity will merge with and into a subsidiary of the Company (the &#x201c;Merger Subs&#x201d;) with BSR, BSV and each Broad Street Entity surviving (collectively, the &#x201c;Mergers&#x201d;). MedAmerica following the completion of the Mergers is referred to herein as the &#x201c;Combined Company.&#x201d; Pursuant to the Merger Agreements, the name of the Combined Company will be changed to &#x201c;Broad Street Realty, Inc.&#x201d; prior to the closing of the Mergers.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 9, 2019, </div>our board of directors approved a proposed amendment to our bylaws to remove Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.2</div> of our bylaws, which prohibited the Company from compensating our directors (the &#x201c;bylaw amendment&#x201d;) and recommended to our stockholders adoption of the bylaw amendment and ratification of past compensation paid by MedAmerica to our directors (the &#x201c;board compensation&#x201d;). Delaware law permits the holders of a majority of our outstanding shares to approve the bylaw amendment and ratify the board compensation by written consent without holding a meeting. The amendment to the By-laws became effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 17, 2019.&nbsp; </div>This amendment had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on previously reported results of operations.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109976
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-325479
us-gaap Net Income Loss
NetIncomeLoss
-264845
us-gaap Net Income Loss
NetIncomeLoss
-296310
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-145081
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-87125
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-267345
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-298810
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-146331
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88375
CY2018Q2 us-gaap Number Of Stores
NumberOfStores
17
us-gaap Operating Income Loss
OperatingIncomeLoss
-263860
us-gaap Operating Income Loss
OperatingIncomeLoss
-295542
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-144589
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-86741
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
CY2018 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.1
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2500
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2500
CY2019Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11014
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33784
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1940005
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22616
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22616
us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Equipment and Furnishings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">Equipment and furnishings are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div> years. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in income for the period statement of operations.</div></div></div></div></div></div></div></div>
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16960
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18576
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112113784
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111848939
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
60000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.71
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.71
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y273D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y313D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y131D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
70000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-225875
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38970
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
641510
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
345200
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-80794
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
432325
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"), requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and disclosures of contingent assets and liabilities at the date and period ending of the financial statements. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568

Files In Submission

Name View Source Status
0001437749-19-016367-index-headers.html Edgar Link pending
0001437749-19-016367-index.html Edgar Link pending
0001437749-19-016367.txt Edgar Link pending
0001437749-19-016367-xbrl.zip Edgar Link pending
ex_151384.htm Edgar Link pending
ex_151385.htm Edgar Link pending
ex_151386.htm Edgar Link pending
ex_151387.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mamp-20190630.xml Edgar Link completed
mamp-20190630.xsd Edgar Link pending
mamp-20190630_cal.xml Edgar Link unprocessable
mamp-20190630_def.xml Edgar Link unprocessable
mamp-20190630_lab.xml Edgar Link unprocessable
mamp-20190630_pre.xml Edgar Link unprocessable
mamp20190630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending